[Experience of therapy with axi-cel CAR-T in an elderly patient suffering from double expressor DLBCL in an advanced stage and refractory to first-line chemoimmunotherapy.]

Abstract

We hereby describe a case of successful therapy with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor T-cells (CAR-T) in an elderly patient suffering from DLBCL refractory to first-line chemoimmunotherapy, with particular reference to the setting of the diagnostic/therapeutic path and collaboration between the Referral center and the CAR-T center.